Orforglipron
Human RCTAlso known as: LY3502970
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
An orally active, non-peptide (small-molecule) GLP-1 receptor agonist. It reported positive phase 3 results in 2025 and has been submitted for regulatory review; it is not yet approved for general use.
Mechanism
A small molecule that activates the GLP-1 receptor directly, avoiding the injection and food-timing constraints of peptide GLP-1 agonists.
Evidence
Phase 3 RCT data (ACHIEVE, ATTAIN programmes) are strong for glycaemic control and weight loss, but it is under review and not yet approved; long-term safety continues to be established.
Community-reported information
Investigational and unapproved outside its regulatory process. No community schedule is presented.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
~24–30 hours (once-daily oral dosing in trials).
Storage
Room temperature (oral tablet formulations in trials).
Commonly reported side effects
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Decreased appetite
Legal status by region
- USNot yet approved; under regulatory review.
- GBNot licensed; investigational.
Legal status changes over time; verify locally before relying on this.